Evidence map›Paper›PMID 42239817›Full record

ArticleKidney medicine2026

Safety and Effectiveness of Daratumumab in Recurrent and De Novo Focal Segmental Glomerulosclerosis After Kidney Transplant.

Rohan V Mehta, Kayla B Evans, Chintan V Shah, Ashutosh Shukla, Amer Belal, Hisham Ibrahim, Kawther Alquadan, Muhannad Leghrouz, Georgios Vrakas, Rahul Mehta and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rohan V MehtaDivision of Nephrology, Hypertension and Renal Transplantation, University of Florida, Gainesville, FL.
Kayla B EvansUniversity of Florida Health Transplant Center, Gainesville, FL.
Chintan V ShahDivision of Nephrology, Hypertension and Renal Transplantation, University of Florida, Gainesville, FL.
Ashutosh ShuklaDivision of Nephrology, Hypertension and Renal Transplantation, University of Florida, Gainesville, FL.
Amer BelalDivision of Nephrology, Hypertension and Renal Transplantation, University of Florida, Gainesville, FL.
Hisham IbrahimDivision of Nephrology, Hypertension and Renal Transplantation, University of Florida, Gainesville, FL.
Kawther AlquadanDivision of Nephrology, Hypertension and Renal Transplantation, University of Florida, Gainesville, FL.
Muhannad LeghrouzDivision of Nephrology, Hypertension and Renal Transplantation, University of Florida, Gainesville, FL.
Georgios VrakasDivision of Kidney- Pancreas and Hepatobiliary Surgery, Department of Surgery, University of Florida, Gainesville, FL.
Rahul MehtaDivision of Hospital Medicine, Department of Internal Medicine, University of Virginia, Charlottesville, VA.
Alfonso SantosDivision of Nephrology, Hypertension and Renal Transplantation, University of Florida, Gainesville, FL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Daratumumab, an anti-CD38 monoclonal antibody targeting plasma cells, has emerged as a potential therapy for recurrent focal segmental glomerulosclerosis (FSGS) after kidney transplantation; however, data on subcutaneous administration and its use in de novo disease are limited. We report 3 kidney transplant recipients with recurrent (n = 1) and de novo (n = 2) FSGS who were plasma exchange-dependent and/or rituximab-resistant and treated with subcutaneous daratumumab. All patients achieved remission, with sustained reductions in albuminuria and stable graft function at follow-up. Treatment was well tolerated, with no injection-related reactions; 1 patient developed transient neutropenia and oral ulcers. Subcutaneous daratumumab may represent a feasible and effective option for recurrent and de novo FSGS after kidney transplantation, including refractory cases, in conjunction with anti-CD20 therapy. Prospective studies are needed to define its role as monotherapy and the durability of response.

Indexed as

Anti-CD38 monoclonal antibodydaratumumabfocal segmental glomerulosclerosis (FSGS)kidney transplantplasma exchangerituximab

Identifiers

PMID42239817
PMCPMC13227183

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.